Adalimumab Xagena

Adalimumab

News

Page 1 of 3

FDA has received reports of malignancies in children using TNF antagonists: The FDA ( Food and Drug Administration ) has received reports of malignancies in children using tumor necrosis factor alpha ( TNF ) blockers, raising concerns of an associated risk and prompting an investigation. Researchers from the FDA set out to identify all reports of malignancy in children usin...
Read Article

Risk of tuberculosis with anti-TNF agents: Treatment with anti-tumor necrosis factor ( TNF ) agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis. Most tuberculosis cases develop ...
Read Article

Rheumatoid arthritis: Golimumab shows promising results in patients who have poor response to other TNF-alpha inhibitors: Golimumab ( Simponi ), a new tumour necrosis factor-alpha ( TNF-alpha ) blocker reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-alpha inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF...
Read Article

Rheumatoid arthritis: treatment with the monoclonal anti-TNF-alpha antibodies Adalimumab and Infliximab linked to increased risk for herpes zoster: Use of monoclonal anti-TNF-alpha antibodies for the treatment of rheumatoid arthritis appears to be associated with an increased risk for herpes zoster. There has been evidence from some studies that patients treated with anti-TNF-alpha agents are at an increased risk of bacterial infections, but...
Read Article

Risk of tuberculosis: higher for patients receiving anti-TNF monoclonal antibody therapy than for those receiving soluble TNF receptor therapy: Treatment with anti-TNF ( tumor necrosis factor ) blockers is recognized as a risk factor for tuberculosis ( TB ) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis. Most tuberculosis cases d...
Read Article

TNF blockers linked to increased risk of lymphoma, leukaemia and new-onset psoriasis: The FDA ( Food and Drug Administration ) is requiring the manufacturers of TNF blockers to update the Boxed Warning in the prescribing information to alert healthcare professionals of an increased risk of lymphoma and other malignancies in children and adolescents treated with TNF blockers. In ad...
Read Article

Anti�TNF-alpha agents may be associated with increased risk for herpes zoster: Anti-tumor necrosis factor alpha ( TNF-alpha ) antibodies for the treatment of rheumatoid arthritis appears to be associated with an increased risk for herpes zoster. There has been evidence from some studies that patients treated with anti�TNF-alpha agents are at an increased risk of bacterial i...
Read Article

Invasive fungal infections associated with TNF-alpha inhibition: Tumor necrosis factor a ( TNF- alpha ) blockade has emerged as a useful therapy for collagen vascular diseases or graft-vs-host disease. Fungal infections complicating such therapy have been reported sporadically. Of the 281 cases of invasive fungal infections associated with TNF-alpha inhibition...
Read Article

FDA: TNF-alpha blockers associated with risk of fungal infections: The FDA ( Food and Drug Administration ) has announced that the manufacturers of Humira ( Adalimumab ), Cimzia ( Certolizumab pegol ), Enbrel ( Etanercept ), and Remicade ( Infliximab ) must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing informati...
Read Article

Serious skin reactions linked to TNF-alpha antagonists: Safety reviews of tumor necrosis factor-alpha ( TNF-a ) antagonists, Infliximab ( Remicade ), Etanercept ( Enbrel ), and Adalimumab ( Humira ) identified rare cases of serious skin reactions, including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, associated with the...
Read Article

Pages:1, 2, 3 Next

Farmaci

Home